{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:39:53Z","timestamp":1777923593209,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Metabolic Syndrome and Related Disorders"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To assess the association of antidepressant (AD) medication use with prevalence and control of cardiovascular (CV) risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data of older adults from the population-based Italian Osservatorio Epidemiologico Cardiovascolare\/Health Examination Survey (OEC\/HES) Study 2008\u20132012 were used. CV risk factors were measured using standardized procedures. Information on clinical features, lifestyles, and medications was collected using standardized questionnaires. Logistic regression models were elaborated to assess associations between AD use and prevalence and control of CV risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Around 2549 participants (age 71.4\u2009\u00b1\u20094.2 years, 51.3% men) were studied; 268 (10.5%) were AD users. Of these, 72.4% used selective serotonin reuptake inhibitors (SSRI). AD users had less favorable CV risk factor profile and were less likely to achieve control of blood pressure and total cholesterol. After multiple adjustment for potentially confounding variables, AD use was associated with greater likelihood of having diabetes (OR\u2009=\u20091.05, 95% CI\u2009=\u20091.02\u20131.10,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.008), hypertension (OR\u2009=\u20091.10, 95% CI\u2009=\u20091.05\u20131.20,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.003), and hypercholesterolemia (OR\u2009=\u20091.08, 95% CI\u2009=\u20091.04\u20131.14,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among participants treated for hypertension and hypercholesterolemia, AD use was associated with poorer control of BP (OR\u2009=\u20091.07, 95% CI\u2009=\u20091.03\u20131.12,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.001) and cholesterol (OR\u2009=\u20091.06, 95% CI\u2009=\u20091.01\u20131.12,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.021). Results persisted virtually unchanged when analyses were restricted to participants on SSRI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>AD use was associated with greater prevalence and poorer control of traditional risk factors for CV disease in a population-based sample of older adults. Such results highlight the need for surveillance of CV risk factors and promotion of healthy lifestyles in older adults with psychopathology and, in particular, in those under AD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/met.2019.0088","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T16:36:27Z","timestamp":1575995787000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Association Between Antidepressant Medication Use and Prevalence and Control of Cardiovascular Risk Factors in Community-Dwelling Older Adults: The Italian Health Examination Survey 2008\u20132012"],"prefix":"10.1177","volume":"18","author":[{"given":"Giovanni","family":"Viscogliosi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Dysmetabolic and Aging-Associated Diseases, National Institute of Health, Rome, Italy."},{"name":"Centre of Epidemiology and Biostatistics, Polytechnic University of Marche, Ancona, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Donfrancesco","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Dysmetabolic and Aging-Associated Diseases, National Institute of Health, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Lo Noce","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Dysmetabolic and Aging-Associated Diseases, National Institute of Health, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Giampaoli","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Dysmetabolic and Aging-Associated Diseases, National Institute of Health, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Vanuzzo","sequence":"additional","affiliation":[{"name":"National Association Hospital Cardiologists, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Carle","sequence":"additional","affiliation":[{"name":"Centre of Epidemiology and Biostatistics, Polytechnic University of Marche, Ancona, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Dysmetabolic and Aging-Associated Diseases, National Institute of Health, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0196-y"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0000000000000583"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.107664"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025140"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318200d70e"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.111195"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-3170-2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/da.22512"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2016.08.020"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1219"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016224"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182088"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291713002778"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487315589011"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1963.03060120024016"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2010.02.006"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1103"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10048"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2007.12.008"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1037\/hea0000529"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115592340"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4085-9"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12057"}],"container-title":["Metabolic Syndrome and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/met.2019.0088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/met.2019.0088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/met.2019.0088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:53:02Z","timestamp":1777668782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/met.2019.0088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1089\/met.2019.0088"],"URL":"https:\/\/doi.org\/10.1089\/met.2019.0088","relation":{},"ISSN":["1540-4196","1557-8518"],"issn-type":[{"value":"1540-4196","type":"print"},{"value":"1557-8518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]}}}